Consent before testing men for prostate cancer - a challenge?

Australian Family Physician

Volumn 34, Issue 10, 2005, Pages 888-

  Hirst, Geoffrey ^a  

^a MATER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; ATTITUDE TO HEALTH; BLOOD; GENERAL PRACTICE; HUMAN; INFORMED CONSENT; MALE; MASS SCREENING; METHODOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; RISK ASSESSMENT; STANDARD;

FAMILY PRACTICE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFORMED CONSENT; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 33644841238     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003;361:1122-8.
2. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;137:917-29.
3. Raffle AE. Information about screening: is it to achieve high uptake or to ensure informed choice? Health Expect 2001;4:92-8.
4. Draisma G, De Koning HJ. Miscan: estimating lead-time and overdetection by simulation. BJU Int 2003;92(Suppl 2):106-11.
5. Albertsen PC, Hanley JA, Fine J. 20 year outcomes following conservative management of clinically localised prostate cancer. JAMA 2005;293:2095-101.
6. Potosky AL, Davis WW, Hoffman RM, et al. Five year outcomes after prostatectomy or radiotherapy for prostate cancer: The Prostate Cancer Outcomes Study. J Natl Cancer Inst 2004;96:1358-67.